Scholarlink

Background <p>Very-early-onset inflammatory bowel disease (VEO-IBD), representing cases diagnosed before age 6&#xa0;years, is increasing in prevalence. Although VEO-IBD often presents as severe, treatment-resistant disease requiring biologic agents, studies showing the effectiveness of biologics, such as ustekinumab (UST) and vedolizumab (VDZ), remain limited.</p> Methods <p>We retrospectively analyzed patients with VEO-IBD treated for at least a year from 13 institutions in Japan, evaluating clinical course including effectiveness of biologics, such as infliximab (IFX), adalimumab (ADL), UST, and VDZ. Patients with monogenic IBD were excluded. Steroid-free clinical remission (SFCR) and treatment persistence were assessed separately for first-line and for second-line or subsequent biologic therapies.</p> Results <p>We studied 101 VEO-IBD patients (56% male; median age, 3.6&#xa0;years), including 40 with Crohn’s disease, 52 with ulcerative colitis, and 9 with unclassified IBD. Biologics were used in 67 patients, most commonly infliximab (IFX; <i>n</i> = 52), followed by UST (<i>n</i> = 38), adalimumab (ADL; <i>n</i> = 23), and VDZ (<i>n</i> = 21). As first-line therapy, IFX and ADL achieved 1-year SFCR rates of 19% and 46%, with persistence rates of 36% and 48%. Despite being used mainly as second-line or subsequent therapies, UST and VDZ showed 1-year SFCR rates of about 45% and 36%, and maintained persistence of 79% and 46%, respectively, with UST demonstrating higher persistence than TNF-α inhibitors (<i>P</i> &lt; 0.01). No discontinuations due to infusion reactions or other adverse events occurred with UST or VDZ.</p> Conclusion <p>UST and VDZ were effective and well tolerated even when used as second-line or subsequent therapies for VEO-IBD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月3日

查看全文
  • Ryusuke Nambu,
  • Itaru Iwama,
  • Ichiro Takeuchi,
  • Shin-ichiro Hagiwara,
  • Yuri Etani,
  • Emiri Kaji,
  • Atsushi Yoden,
  • Fumihiko Kakuta,
  • Yusuke Hoshi,
  • Naoya Tsumura,
  • Tatsuki Mizuochi,
  • Hideki Kumagai,
  • Koji Yokoyama,
  • Takuya Nishizawa,
  • Masaaki Usami,
  • Yugo Takaki,
  • Ryo Ebana,
  • Shingo Kurasawa,
  • Hiroki Fujikawa,
  • Takashi Ishige,
  • Takahiro Kudo,
  • M. Masashi Yoshida,
  • Hirotaka Shimizu,
  • Katsuhiro Arai

摘要

Background

Very-early-onset inflammatory bowel disease (VEO-IBD), representing cases diagnosed before age 6 years, is increasing in prevalence. Although VEO-IBD often presents as severe, treatment-resistant disease requiring biologic agents, studies showing the effectiveness of biologics, such as ustekinumab (UST) and vedolizumab (VDZ), remain limited.

Methods

We retrospectively analyzed patients with VEO-IBD treated for at least a year from 13 institutions in Japan, evaluating clinical course including effectiveness of biologics, such as infliximab (IFX), adalimumab (ADL), UST, and VDZ. Patients with monogenic IBD were excluded. Steroid-free clinical remission (SFCR) and treatment persistence were assessed separately for first-line and for second-line or subsequent biologic therapies.

Results

We studied 101 VEO-IBD patients (56% male; median age, 3.6 years), including 40 with Crohn’s disease, 52 with ulcerative colitis, and 9 with unclassified IBD. Biologics were used in 67 patients, most commonly infliximab (IFX; n = 52), followed by UST (n = 38), adalimumab (ADL; n = 23), and VDZ (n = 21). As first-line therapy, IFX and ADL achieved 1-year SFCR rates of 19% and 46%, with persistence rates of 36% and 48%. Despite being used mainly as second-line or subsequent therapies, UST and VDZ showed 1-year SFCR rates of about 45% and 36%, and maintained persistence of 79% and 46%, respectively, with UST demonstrating higher persistence than TNF-α inhibitors (P < 0.01). No discontinuations due to infusion reactions or other adverse events occurred with UST or VDZ.

Conclusion

UST and VDZ were effective and well tolerated even when used as second-line or subsequent therapies for VEO-IBD.